Lemire is wrong. TAME and MILES are different. MILES is intended to just examine short-term responses (look at the registered endpoints: “Primary: Gene expression. (changes in gene expression in muscle and adipose tissue with RNA Sequencing (RNA-Seq) [ Time Frame: 12 weeks treatment ]”); TAME is intended to be a long-term 5+-year study looking for reduction in cancer and heart disease. https://clinicaltrials.gov/ct2/show/NCT02432287 is MILES, and TAME is AFAIK not yet registered on clinicaltrials.gov because they were working on approval & funding first and have not yet published a draft protocol or begun recruiting. (When I was trying to do a power analysis for TAME, I went looking, but all I found was some media mentions which suggest that a protocol has been developed as part of the application process, as one would expect, but that it’s nowhere publicly available.)
Lemire is wrong. TAME and MILES are different. MILES is intended to just examine short-term responses (look at the registered endpoints: “Primary: Gene expression. (changes in gene expression in muscle and adipose tissue with RNA Sequencing (RNA-Seq) [ Time Frame: 12 weeks treatment ]”); TAME is intended to be a long-term 5+-year study looking for reduction in cancer and heart disease. https://clinicaltrials.gov/ct2/show/NCT02432287 is MILES, and TAME is AFAIK not yet registered on clinicaltrials.gov because they were working on approval & funding first and have not yet published a draft protocol or begun recruiting. (When I was trying to do a power analysis for TAME, I went looking, but all I found was some media mentions which suggest that a protocol has been developed as part of the application process, as one would expect, but that it’s nowhere publicly available.)
Yeah, I confused the cheap talk of clinicaltrials.gov accepting targeting aging with the FDA accepting aging as a potential indication.